The Traders Cafe with Zak Mir

Zak Mir talks to Riverfort's Investment director Nicholas Lee and Smarttech247's CEO Ronan Murphy regarding Riverfort's investment in the cybersecurity company.

Maurice Healy speaks regarding his software company which specialises in intergrating accounts payable for corporates using its analytical technology. He discusses the landscape in the sector, especially in the wake of the pandemic, and given the ongoing growth at the company. At least part of any fresh growth could be delivered by acquisition. 

Steve Cracknell, CEO Insig AI talks ahead of the first day of dealings on AIM, and the reverse takeover of Catena plc. He discusses the events which have led to the AI and machine learning company serving the asset management industry gaining a commanding position in its space.

Guy Meyer, CEO Catenae Innovation discusses the Hyperneph acquisition and what it brings to his company and the way it does business. He also describes the implications of the post pandemic environment for Catenae in driving its agenda.

Zak Mir is joined by regulars Phil Carroll, Albert Arthur and Kevin Hornsby with more stock market banter. This week they are joined by Gerrard Brandon, CEO Deepverge (DVRG) and Non Executive Chairman Microsaic.

Minutes of Podcast:

57s Phil’s  week on

2.07 Forbes Ventures (FOR)

4.07 Caerus (CMRS) and Jubilee Metals (JLP)

6.01 Rambler (RMM)

7.15 Zak on CMRS

8.26 on RMM

8.45 Phil on RMM

9.15 on CMRS’s large trade

10.41 Albert’s week on

10.55 Synairgen (SNG)

11.38 Deepverge (DVRG)

14.05 Gerry Brandon on Deepverge

20.55 Albert and Gerry talk about the rapid breath test

25.00 Gerry on the hospitality industry’s needs

27.00 The spike protein, Avacta (AVCT) and the Aptamer Group

28.45 Uses for doping

29.19 Gerry on Microsaic (MSYS)

29.49 Gerry on AI

30.28 Gerry on data

32.59 Gerry’s background

34.15 Phil on Faithless

34.40 Gerry on Integumen

35.28 Kevin asks Gerry about the 4 second test

37.52 Albert asks Gerry about test accuracy and PCR

40.38 Kevin asks Gerry the cost of the test

44.07 Gerry on potential unicorns

49.47 Phil: skin the largest organ

50.51 Gerry’s Rosetta Stone

52.25 Phil wants to join Skintrustclub.com

55.08 Gerry on the gut biome

56.29 Kevin asks Gerry what will make people invest in Deepverge?

58.59 Albert asks Gerry about revenue

62.08 Zak to Gerry: is Deepverge too sprawling to understand?

64.43 Zak on the China Resources deal

66.00 Albert on the revenue flip

66.27 Gerry on investing in growth

71.21 Kevin’s week: Zoetic (ZOE), Caerus (CMRS), Valereum (VLRM), Alpha Growth (ALGW

75.31 Kevin on David Lenigas, Siam Kidd and NFTs

76.35 Albert on Synairgen (SNG), the markets and the Green List

78.57 Phil on Oriole Resources (ORR)

81.09 Zak's lunch with Gareth Cave plus Chamberlain (CMH) and the FTSE 100

Colin Bird, Executive Chairman Galileo Resources (GLR), runs through the company's current news as well as discussing other mining companies in the Bird stable. They include Xtract Resources (XTR), Bezant Resources (BZT) and Jubilee Metals (JLP) in the wake of the latest deal with Caerus Mineral Resources (CMRS).

Louis Coetzee, Non Executive Chairman Mast Energy (MAST) discusses the latest operational update from the reserve power group and the prospect of an accelerated pipeline of deals in the aftermath of the recent stock market listing.

Dr. Gary S. Jacob, Chief Executive Officer of OKYO discusses the latest from the dry eye treatment company regarding positive results of OK-201, a non-opioid analgesic drug candidate. He also runs through developments at OKYO since he became CEO earlier this year, as well as timelines to future milestones at the company.